SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of INmune Bio, Inc. - INMB
New York, New York--(Newsfile Corp. - May 28, 2022) - Pomerantz LLP is investigating claims on behalf of investors of INmune Bio, Inc. ("INmune" or the "Company") (NASDAQ: INMB). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.
The investigation concerns whether INmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On May 23, 2022, INmune issued a press release "announc[ing] that on May 20, 2022, the Company was informed via e-mail communication from the U.S. Food and Drug Administration (FDA) requesting additional information around Chemistry Manufacturing and Controls (CMC) of the newly manufactured XPro1595 (XPro™). As part of the communication, the Agency placed the Company's Investigational New Drug (IND) application to initiate its Phase 2 clinical trial of XPro™ in patients with Alzheimer's Disease (AD) in the U.S. on clinical hold. The FDA indicated they will provide an official clinical hold letter to INmune in approximately 30 days."
On this news, INmune's stock price fell $1.79 per share, or 24.62%, to close at $5.48 per share on May 24, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Robert S. Willoughby
888-476-6529 ext. 7980
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/125734